T he data on the efficacy of directly acting antiviral agent (DAA) regimens in hepatitis B virus (HBV)/ hepatitis C virus (HCV) chronic co-infection are very few, and suggest a possible reactivation of HBV infection (rHBV) after HCV control. [1] [2] [3] The efficacy of DAA-based regimens was evaluated in 29 hepatitis B surface antigen/anti-HCV/HCV RNA-positive patients in terms of sustained virologic response for HCV and of rHBV.
Methods
In a prospective multicenter study all 29 consecutive, DAA-naive, HCV RNA-positive patients with HBV/HCV co-infection who were treated from April 2015 to March 2016 with a DAA-based regimen were enrolled.
The indication for antiviral therapy and the choice of the DAA-based regimen was made according to international guidelines 4 and local availability. A virologic rHBV was diagnosed when the HBV viral load increased at least 1 log compared with baseline or became positive when previously undetectable. A biochemical or clinical rHBV were defined, at least 2-fold increase in the serum value of alanine aminotransferase (ALT) compared with baseline value and as the development of signs or symptoms of hepatic decompensation, associated with a virologic rHBV, respectively.
Results
Twenty (72%) patients were men, and the median age was 61 years (range, 38-80 y). Most (n ¼ 25) patients had cirrhosis (23 in Child-Pugh stage A and 2 in Child-Pugh stage B); 6 (21.4%) patients had a history of liver transplantation. At enrollment only 1 patient was hepatitis B e antigen positive and 5 patients were HBV DNA positive. At the time when the DAA regimen was started, 16 (55.2%) patients were receiving nucleos(t)ide treatment (NUC group; all HBV DNA negative) and 13 patients were not (NUC-sparing group; 5 HBV DNA positive; range, 28-653 IU/mL; and 8 negative).
Of the 29 patients enrolled, 23 (79.3%) experienced a rapid virologic response (HCV RNA negative at month 1 of treatment), all were HCV RNA negative at the end of HCV treatment, and 27 (93.1%) had a sustained virologic response at week 12 after HCV treatment.
No difference in the demographic, virologic, and clinical characteristics was observed between the 16 patients in the NUC group and the 13 patients in the NUC-sparing group. However, in the NUC group, no patient showed any virologic, clinical, or biochemical rHBV. Of the 13 patients in the NUC-sparing group, 8 remained HBV DNA negative during observation and 5 showed rHBV (2 at the first month of DAA treatment, 1 at month 3, 1 at month 4, and 1 at month 1 after stopping DAA). The characteristics of the 5 patients who developed rHBV are shown in Table 1 . NUC rescue treatment was started quickly for all patients with the exception of the patient with the reactivation at the end of therapy who had a low HBV titer and no biochemical rHBV (patient 1). In patient 2, HBV DNA became negative after starting NUC rescue therapy and no biochemical or clinical rHBV was observed. A biochemical rHBV was observed in patients 3, 4, and 5. Patient 3 developed rHBV during the third month of treatment with sofosbuvir þ ledipasvir. After NUC rescue therapy with entecavir the patient promptly became HBV DNA negative, ALT level normalized, and there was no sign of hepatic decompensation. Instead, in patients 4 and 5 rHBV was observed at months 4 and 1 of DAA treatment, respectively. With NUC rescue therapy (tenofovir and entecavir, respectively) HBV DNA became negative at days 180 and 90 of DAA, but a severe biochemical and clinical rHBV was observed: development of jaundice, ascites, and portosystemic encephalopathy in patient 4, who for this hepatic failure underwent orthotopic liver transplantation; and an increase in ALT level of 16 times the baseline value with development of jaundice and ascites in patient 5.
Discussion
The present investigation showed that DAA regimens were effective in suppressing HCV replication in patients with chronic HBV/HCV co-infection. Similarly, DAA treatment is effective and safe for patients taking an NUC at the same time, however, nearly 40% of the patients in the NUC-sparing group developed rHBV and prompt NUC rescue therapy did not prevent hepatic liver failure in 2 cases. HBV reactivation has been described in patients with HBV/HCV co-infection who cleared HCV RNA with interferon or DAA-based treatment. [1] [2] [3] [5] [6] [7] More recently, in a systematic review the incidence rate of rHBV was similar between patients treated with interferon-based therapy (14.5%) and a DAA regimen (12.2%); however, it was reported to occur much earlier in the latter and associated with a biochemical and/or clinical reactivation only in those treated with a DAA regimen (12.2% vs 0%). 8 In conclusion, rHBV may arise in patients without control of HBV replication by a NUC, with potentially severe liver damage. Thus, it seems reasonable to suggest NUC therapy for all hepatitis B surface antigen/ anti-HCV-positive patients treated with a DAA regimen, especially patients with a severe disease Table 1 . Dac, daclatasvir; Ent, entecavir; F, female; HBeAg, hepatitis B e antigen; Led, ledipasvir; M, male; OLT, orthotopic liver transplantation; par-r/mb/das, paritaprevir-ritonavir/ombitasvir/dasabuvir; Sim, simpeprevir; Sof, sofosbuvir; SVR, sustained virologic response; SVR24, sustained virologic response at 24 hours; Tdf, tenofovir; UNL, upper normal limit.
